Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J.
Liang EC, et al. Among authors: shadman m.
Blood Adv. 2023 Nov 28;7(22):6990-7005. doi: 10.1182/bloodadvances.2023011399.
Blood Adv. 2023.
PMID: 37774014
Free PMC article.
Clinical Trial.